Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2014 May 1;30(5):468–475. doi: 10.1089/aid.2013.0197

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright 2014, Mary Ann Liebert, Inc.

PMC Copyright notice

FIG. 2. — Percentage of HLA-B*07:02 subjects making IFN-γ ELISpot responses to 16 B-clade and C-clade-specific HLA-B*07:02-restricted optimal epitopes in B-clade and C-clade-infected subjects. (A) Protein-specific and (B–D) optimal epitope-specific IFN-( ELISpot responses tested in B-clade and C-clade-infected HLA-B*07:02 individuals using a cut-off of 100 spot-forming units per million PBMCs. (E) Comparing magnitudes of protein-specific responses expressed as SFU/million input PBMCs with horizontal lines representing median values. (F) Showing the mean number of epitopes targeted per individual for C-clade and B-clade-infected individuals. Significant differences (p<0.05) by Fisher's exact test (A–C), Mann–Whitney U test (E), and unpaired t-test (F). Individuals coexpressing HLA-B*39:10, B*42:01, B*81:01, and Cw*08:02 were excluded for TL9-p24 analysis as these HLA alleles also restrict TL9-p24.